WATERTOWN, Mass.--(BUSINESS WIRE)--Selecta Biosciences, Inc. has completed a $38 million Series E equity financing, will be used to advance multiple product candidates from Selecta’s Synthetic Vaccine Particle (SVP) platform.
| < Prev | Next > |
|---|
- Hunt for Queen's Wharf developer commences
- Magazine seeks writers for online column in U.S.A, U.K., Asia & Australia. Writers wanted
- Queensland unit and townhouse sales climb
- Perth median house price at new record
- Don’t let a bad credit score ruin your chances of a home loan
- The Importance of Communication for Business Success
- Respected local restaurateurs are the icing on the Tweed River Art Gallery
- Lonely Planet names Kimberley as world’s second top tourism region for 2014
- The Workers Launch Balmain's Biggest Laugh Free Live Comedy
- UK Innovator Visa: Getting Endorsement
- Businesses
- The Global Forest Industry This Quarter
- Katter calls for better delivery of drought assistance
- Surplus signals time for NSW Government to cut stamp duty
- Jazz Degustation + The Cellar Jazz Jam
- Record harvest ensures city fruit and veg supplies
- ACCC action after chicken companies made false claims
- Progress for Canning Basin exploration
- Commercial gas expansion boosts WA economy
- Vegan Australia says no to Bacon Week
- New agreement on environmental assessments with the Commonwealth Government
- 5 Foolproof Tips for a More Productive You
- How to Successfully Automate your Workflow
- King Kong declared Australia’s most innovative digital marketing agency in 2019
- Text broker Australia writing service
- Major Project Status to the Mount Peake project in Central Australia
- 10 Best Business Website Builders in Australia
- New Year's resolutions for your business
- Port expansion a boost for Pilbara iron ore exports
- Rio Tinto expands iron ore resources in Pilbara
- Natural Resources Institute appoints food security expert
